An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1-84) is overproduced in parathyroid carcinoma

Clinical Chemistry

Volumn 53, Issue 8, 2007, Pages 1470-1476

  Rubin, Mishaela R ^a   Silverberg, Shonni J ^a   D'Amour, Pierre ^b   Brossard, Jean Hugues ^b   Rousseau, Louise ^b   Sliney Jr , James ^a   Cantor, Tom ^c   Bilezikian, John P ^a  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF MONTREAL   (Canada)

^c Scantibodies Laboratory Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; CINACALCET; PARATHYROID HORMONE;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE DETERMINATION; HORMONE SYNTHESIS; HUMAN; MALE; PARATHYROID CARCINOMA; PRIMARY HYPERPARATHYROIDISM; QUANTITATIVE ANALYSIS; SECONDARY HYPERPARATHYROIDISM;

EID: 34547626814     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.085506     Document Type: Article

References (11)

1. Gao P, Scheibel S, D'Amour P, John MR, Rao SD, Schmidt-Gayk H, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16:605-14.
2. D'Amour P, Brossard JH, Rousseau L, Roy L, Gao P, Cantor T. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003;49:2037-44.
3. D'Amour P, Brossard JH, Rakel A, Rousseau L, Albert C, Cantor T. Evidence that the amino-terminal composition of non-(1-84) parathyroid hormone fragments starts before position 19. Clin Chem 2005;51:169-76.
4. Rakel A, Brossard JH, Patenaude JV, Albert C, Nassif E, Cantor T, et al. Overproduction of an amino-terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery. Clin Endocrinol 2005;62:721-7.
5. Arakawa T, D'Amour P, Rousseau L, Brossard J, Sakai M, Kasumoto H, et al. Overproduction and secretion of a novel aminoterminal form of parathyroid hormone from a severe type of parathyroid hyperplasia in uremia. Clin J Am Soc Nephrol 2006; 1:525-31.
6. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Juppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999;84: 4287-90.
7. Bennett HP, Solomon S, Goltzman D. Isolation and analysis of human parathyrin in parathyroid tissue and plasma: use of reversed-phase liquid chromatography. Biochem J 1981;197:391-400.
8. Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle JC. Unexpected serum parathyroid hormone profiles in some patients with primary hyperparathyroidism. Clin Chem 2006;52: 757-60.
9. D'Amour P, Brossard JH, Rousseau L, Nguyen-Yamamoto L, Nassif E, Lazure C, et al. Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int 2005;68:998-1007.
10. Rabbani SA, Kremer R, Bennett HP, Goltzman D. Phosphorylation of parathyroid hormone by human and bovine parathyroid glands. J Biol Chem 1984;259:2949-55.
11. Tanaka M, Itoh K, Matsushita K, Matsushita K, Fujii H, Fukagawa M. Normalization of reversed bio-intact-PTH(1-84)/intact-PTH ratio after parathyroidectomy in a patient with severe secondary hyperparathyroidism. Clin Nephrol 2005;64:69-72.